TY - JOUR
T1 - Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality
T2 - an individual participant meta-analysis
AU - Danesh, John
AU - Lewington, Sarah
AU - Thompson, Simon G
AU - Lowe, Gordon D O
AU - Collins, Rory
AU - Kostis, J B
AU - Wilson, A C
AU - Folsom, A R
AU - Wu, K
AU - Benderly, M
AU - Goldbourt, U
AU - Willeit, J
AU - Kiechl, S
AU - Yarnell, J W G
AU - Sweetnam, P M
AU - Elwood, P C
AU - Cushman, M
AU - Psaty, B M
AU - Tracy, R P
AU - Tybjaerg-Hansen, A
AU - Haverkate, F
AU - de Maat, M P M
AU - Fowkes, F G R
AU - Lee, A J
AU - Smith, F B
AU - Salomaa, V
AU - Harald, K
AU - Rasi, R
AU - Vahtera, E
AU - Jousilahti, P
AU - Pekkanen, J
AU - D'Agostino, R
AU - Kannel, W B
AU - Wilson, P W F
AU - Tofler, G
AU - Arocha-Piñango, C L
AU - Rodriguez-Larralde, A
AU - Nagy, E
AU - Mijares, M
AU - Espinosa, R
AU - Rodriquez-Roa, E
AU - Ryder, E
AU - Diez-Ewald, M P
AU - Campos, G
AU - Fernandez, V
AU - Torres, E
AU - Marchioli, R
AU - Rosengren, A
AU - Rosenberg, R D
AU - Brunner, E
AU - Fibrinogen Studies Collaboration
PY - 2005/10/12
Y1 - 2005/10/12
N2 - CONTEXT: Plasma fibrinogen levels may be associated with the risk of coronary heart disease (CHD) and stroke.OBJECTIVE: To assess the relationships of fibrinogen levels with risk of major vascular and with risk of nonvascular outcomes based on individual participant data.DATA SOURCES: Relevant studies were identified by computer-assisted searches, hand searches of reference lists, and personal communication with relevant investigators.STUDY SELECTION: All identified prospective studies were included with information available on baseline fibrinogen levels and details of subsequent major vascular morbidity and/or cause-specific mortality during at least 1 year of follow-up. Studies were excluded if they recruited participants on the basis of having had a previous history of cardiovascular disease; participants with known preexisting CHD or stroke were excluded.DATA EXTRACTION: Individual records were provided on each of 154,211 participants in 31 prospective studies. During 1.38 million person-years of follow-up, there were 6944 first nonfatal myocardial infarctions or stroke events and 13,210 deaths. Cause-specific mortality was generally available. Analyses involved proportional hazards modeling with adjustment for confounding by known cardiovascular risk factors and for regression dilution bias.DATA SYNTHESIS: Within each age group considered (40-59, 60-69, and > or =70 years), there was an approximately log-linear association with usual fibrinogen level for the risk of any CHD, any stroke, other vascular (eg, non-CHD, nonstroke) mortality, and nonvascular mortality. There was no evidence of a threshold within the range of usual fibrinogen level studied at any age. The age- and sex- adjusted hazard ratio per 1-g/L increase in usual fibrinogen level for CHD was 2.42 (95% confidence interval [CI], 2.24-2.60); stroke, 2.06 (95% CI, 1.83-2.33); other vascular mortality, 2.76 (95% CI, 2.28-3.35); and nonvascular mortality, 2.03 (95% CI, 1.90-2.18). The hazard ratios for CHD and stroke were reduced to about 1.8 after further adjustment for measured values of several established vascular risk factors. In a subset of 7011 participants with available C-reactive protein values, the findings for CHD were essentially unchanged following additional adjustment for C-reactive protein. The associations of fibrinogen level with CHD or stroke did not differ substantially according to sex, smoking, blood pressure, blood lipid levels, or several features of study design.CONCLUSIONS: In this large individual participant meta-analysis, moderately strong associations were found between usual plasma fibrinogen level and the risks of CHD, stroke, other vascular mortality, and nonvascular mortality in a wide range of circumstances in healthy middle-aged adults. Assessment of any causal relevance of elevated fibrinogen levels to disease requires additional research.
AB - CONTEXT: Plasma fibrinogen levels may be associated with the risk of coronary heart disease (CHD) and stroke.OBJECTIVE: To assess the relationships of fibrinogen levels with risk of major vascular and with risk of nonvascular outcomes based on individual participant data.DATA SOURCES: Relevant studies were identified by computer-assisted searches, hand searches of reference lists, and personal communication with relevant investigators.STUDY SELECTION: All identified prospective studies were included with information available on baseline fibrinogen levels and details of subsequent major vascular morbidity and/or cause-specific mortality during at least 1 year of follow-up. Studies were excluded if they recruited participants on the basis of having had a previous history of cardiovascular disease; participants with known preexisting CHD or stroke were excluded.DATA EXTRACTION: Individual records were provided on each of 154,211 participants in 31 prospective studies. During 1.38 million person-years of follow-up, there were 6944 first nonfatal myocardial infarctions or stroke events and 13,210 deaths. Cause-specific mortality was generally available. Analyses involved proportional hazards modeling with adjustment for confounding by known cardiovascular risk factors and for regression dilution bias.DATA SYNTHESIS: Within each age group considered (40-59, 60-69, and > or =70 years), there was an approximately log-linear association with usual fibrinogen level for the risk of any CHD, any stroke, other vascular (eg, non-CHD, nonstroke) mortality, and nonvascular mortality. There was no evidence of a threshold within the range of usual fibrinogen level studied at any age. The age- and sex- adjusted hazard ratio per 1-g/L increase in usual fibrinogen level for CHD was 2.42 (95% confidence interval [CI], 2.24-2.60); stroke, 2.06 (95% CI, 1.83-2.33); other vascular mortality, 2.76 (95% CI, 2.28-3.35); and nonvascular mortality, 2.03 (95% CI, 1.90-2.18). The hazard ratios for CHD and stroke were reduced to about 1.8 after further adjustment for measured values of several established vascular risk factors. In a subset of 7011 participants with available C-reactive protein values, the findings for CHD were essentially unchanged following additional adjustment for C-reactive protein. The associations of fibrinogen level with CHD or stroke did not differ substantially according to sex, smoking, blood pressure, blood lipid levels, or several features of study design.CONCLUSIONS: In this large individual participant meta-analysis, moderately strong associations were found between usual plasma fibrinogen level and the risks of CHD, stroke, other vascular mortality, and nonvascular mortality in a wide range of circumstances in healthy middle-aged adults. Assessment of any causal relevance of elevated fibrinogen levels to disease requires additional research.
KW - Adult
KW - Aged
KW - Cause of Death
KW - Coronary Disease/blood
KW - Fibrinogen/metabolism
KW - Humans
KW - Middle Aged
KW - Myocardial Infarction/blood
KW - Proportional Hazards Models
KW - Risk
KW - Stroke/blood
KW - Vascular Diseases/blood
UR - https://www.scopus.com/pages/publications/84926426742
U2 - 10.1001/jama.294.14.1799
DO - 10.1001/jama.294.14.1799
M3 - Review
C2 - 16219884
SN - 0002-9955
VL - 294
SP - 1799
EP - 1809
JO - JAMA - Journal of the American Medical Association
JF - JAMA - Journal of the American Medical Association
IS - 14
ER -